Drug Discovery World
Now entering its 18th year, DDW stands out as the only truly global publication dedicated to all facets of drug discovery and development. It has earned a reputation as an essential journal within the industry, respected by professionals in the field. DDW is well-known for featuring insights from some of the top experts in the industry, providing a platform for these thought leaders to discuss and stimulate conversations around the pressing challenges related to the technological, strategic, and business aspects of the pharmaceutical and biopharmaceutical sectors. The journal operates on the principle of "Turning Science into Business." The publication explores the latest advancements in science and technology while focusing on their commercial implications. It aims to assess whether these innovations can genuinely enhance the drug discovery and development process, ultimately lowering costs and reducing failure rates, all while accelerating the introduction of new and effective therapies to the market. What sets DDW apart is its ability to engage a worldwide audience, from laboratory professionals to corporate leaders, helping them grasp new technologies and strategies and understand their potential impact on their specific areas of business.
Outlet metrics
Global
#1132983
United Kingdom
#214610
Science and Education/Biology
#425
Articles
-
1 week ago |
ddw-online.com | Megan Thomas
This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA” and “The microbiome in precision medicine”.
-
1 week ago |
ddw-online.com | Diana Spencer
Scientists in the UK and Belgium have discovered new insights into how four different anti-amyloid drugs interact with amyloid beta protein, revealing why the drugs have had varying levels of success at treating Alzheimer’s disease. Amyloid beta is one of the toxic proteins which builds up in clumps or ‘aggregates’ in the brains of people affected by Alzheimer’s. Several drugs targeting the protein have been tested in trials over recent years.
-
1 week ago |
ddw-online.com | Diana Spencer
A new study from researchers at Lund University in Sweden and Imperial College London suggests that treating patients earlier with a combination of statins and the cholesterol-lowering drug ezetimibe could prevent thousands of new heart attacks. For those who survive a heart attack, the risk of a new heart attack is greatest in the first year after the initial event. The current treatment guidelines for patients are high-potency statins immediately after a heart attack.
-
1 week ago |
ddw-online.com | Diana Spencer
Scientists at the Wellcome Sanger Institute in collaboration with Pacific Biosciences (PacBio) have launched a new initiative to map how gene activity shapes the immune system. It is hoped that the project will identify new therapeutic targets for conditions such as inflammatory bowel disease (IBD).
-
1 week ago |
ddw-online.com | Diana Spencer
DDW Editor Reece Armstrong looks at how advances in stem cells, organoids and 3D cell cultures are affecting drug discovery and development. Stem cells, organoids and 3D cell cultures have emerged as promising tools that scientists can use to better understand disease and how drugs function within the human body.
Drug Discovery World journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Website
http://ddw-online.com/Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →